NO20002697L - Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen - Google Patents
Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-genInfo
- Publication number
- NO20002697L NO20002697L NO20002697A NO20002697A NO20002697L NO 20002697 L NO20002697 L NO 20002697L NO 20002697 A NO20002697 A NO 20002697A NO 20002697 A NO20002697 A NO 20002697A NO 20002697 L NO20002697 L NO 20002697L
- Authority
- NO
- Norway
- Prior art keywords
- diagnostic
- variation
- diseases caused
- therapeutic preparation
- lkb1 gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP34425697 | 1997-11-27 | ||
JP28035798 | 1998-10-01 | ||
PCT/JP1998/005357 WO1999028459A1 (fr) | 1997-11-27 | 1998-11-27 | Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20002697D0 NO20002697D0 (no) | 2000-05-26 |
NO20002697L true NO20002697L (no) | 2000-07-27 |
Family
ID=26553739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20002697A NO20002697L (no) | 1997-11-27 | 2000-05-26 | Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen |
Country Status (6)
Country | Link |
---|---|
US (1) | US6800436B1 (fr) |
EP (1) | EP1036844A4 (fr) |
AU (1) | AU750564B2 (fr) |
CA (1) | CA2311414A1 (fr) |
NO (1) | NO20002697L (fr) |
WO (1) | WO1999028459A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1186232A4 (fr) | 1999-05-31 | 2004-11-10 | Chugai Pharmaceutical Co Ltd | Animaux rompant le gene lkb1 |
AU2001271067A1 (en) * | 2000-07-19 | 2002-01-30 | Chugai Seiyaku Kabushiki Kaisha | Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound |
DK1633883T3 (da) * | 2003-06-17 | 2009-01-26 | Medical Res Council | Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet |
CN101072883B (zh) * | 2004-12-08 | 2012-05-23 | 安万特药物公司 | 测量对多西他赛抗药性或敏感性的方法 |
CA2611788A1 (fr) * | 2005-06-30 | 2007-01-11 | Syngenta Participations Ag | Procedes de criblage de polymorphismes d'hybridation specifiques de gene (gshp) et leur utilisation dans la cartographie genetique et le developpement d'un marqueur |
BR112012019459A2 (pt) * | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法 |
WO2014172432A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Polythérapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer |
EA029072B1 (ru) | 2013-04-17 | 2018-02-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты |
JP6382949B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法 |
MX2015014589A (es) | 2013-04-17 | 2016-04-25 | Signal Pharm Llc | Tratamiento de cancer con dihidropirazino-pirazinas. |
WO2014172426A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Traitement du cancer par des dihydropyrazino-pyrazines |
BR112015026021A2 (pt) | 2013-04-17 | 2017-07-25 | Signal Pharm Llc | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer |
NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5709999A (en) * | 1994-08-12 | 1998-01-20 | Myriad Genetics Inc. | Linked breast and ovarian cancer susceptibility gene |
EP0816501B1 (fr) * | 1995-03-16 | 2005-06-01 | Chugai Seiyaku Kabushiki Kaisha | Codage de la proteine kinase par l'adn |
JPH08308586A (ja) * | 1995-03-16 | 1996-11-26 | Chugai Pharmaceut Co Ltd | プロテインキナーゼをコードするdna |
-
1998
- 1998-11-27 WO PCT/JP1998/005357 patent/WO1999028459A1/fr not_active Application Discontinuation
- 1998-11-27 AU AU12620/99A patent/AU750564B2/en not_active Ceased
- 1998-11-27 EP EP98955971A patent/EP1036844A4/fr not_active Withdrawn
- 1998-11-27 CA CA002311414A patent/CA2311414A1/fr not_active Abandoned
- 1998-11-27 US US09/555,166 patent/US6800436B1/en not_active Expired - Fee Related
-
2000
- 2000-05-26 NO NO20002697A patent/NO20002697L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2311414A1 (fr) | 1999-06-10 |
EP1036844A4 (fr) | 2002-12-04 |
WO1999028459A1 (fr) | 1999-06-10 |
AU750564B2 (en) | 2002-07-25 |
AU1262099A (en) | 1999-06-16 |
US6800436B1 (en) | 2004-10-05 |
EP1036844A1 (fr) | 2000-09-20 |
NO20002697D0 (no) | 2000-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20002697L (no) | Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen | |
ATE322269T1 (de) | Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung | |
NO20016364D0 (no) | Fremgangsmåte og anordning for noninvasiv blodanalysemåling | |
DE60313602D1 (de) | N-iPHENYL(PIPERIDIN-2-YL)METHYLöBENZAMIDDERIVATE,VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE ANWENDUNG | |
DE60239669D1 (de) | Sojabohnenprotein, verfahren zu seiner herstellung sowie dessen säure enthaltende proteinnahrungsmittel | |
NO974521L (no) | Preparat for grunning av dentale og biologiske substrater | |
NO20012689D0 (no) | Nye fluider og teknikker for matriks syrebehandling | |
DK0739898T3 (da) | Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
DE60336264D1 (de) | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung | |
ATE242762T1 (de) | Acrylonitril-derivate, verfahren zu ihrer herstellung und diese enthaltende schädlingsbekämpfungsmittel | |
IS5852A (is) | Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum | |
ATE267202T1 (de) | 1,4-diazabicyclo(3.2.2)nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
NO961000D0 (no) | Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike | |
ATE290366T1 (de) | Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung | |
AU2002332102A1 (en) | System, method, and apparatus for disease susceptibility testing | |
AU6225999A (en) | Disposable training pant, apparatus and method for manufacturing it | |
AU2002239664A1 (en) | Method for drug development using individual patient response | |
WO2002063951A3 (fr) | Modelisation de maladies chez l'homme a l'aide d'un transfert de gene somatique | |
DE60003662D1 (de) | Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
AU2000279747A1 (en) | Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion | |
ATE294181T1 (de) | (3,4-a:3,4-c)carbazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
AU2003276727A1 (en) | Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes | |
AU2003284166A1 (en) | Methods for diagnosing and treating pre-term labor | |
DE59911949D1 (de) | Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament | |
DE69516534D1 (de) | Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |